Global Search | Novartis United States of America

Sort by

Relevance

Newest first

Oldest first

Hide Filters

Showing 683 results

Media Release / May 15, 2008

Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
Media Release / Mar 10, 2008

VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy

- Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen- Femara only member of aromatase inhibitor class…
Media Release / Mar 10, 2008

VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
Media Release / Feb 28, 2008

Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy

- Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus- Everolimus (RAD001) tablet, taken once daily,…
Media Release / Feb 28, 2008

Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
Media Release / Jan 21, 2008

Video and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure

- Tekturna HCT combines first approved direct renin inhibitor with the diuretic hydrochlorothiazide (HCTZ) in a single tablet- Data show combination of Tekturna and HCTZ resulted in significant…
Media Release / Jan 21, 2008

Video and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure
Media Release / Dec 09, 2007

Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment

- Risk of disease progression continues to drop from the second year of treatment; no patients taking Gleevec in sixth year progressed from initial disease phase- Long-term survival trend may suggest…
Media Release / Dec 09, 2007

Photo: New Data Show Gleevec® Halts Progression to Advanced Stages of Life-Threatening Form of Leukemia in Sixth Year of Treatment
Media Release / Aug 17, 2005

2005 Release

2005 Release SubHeadlineBody Copy Here